TORONTO, April 23, 2018 -- Axiom Real-Time Metrics, premier provider of unified eClinical solutions and services, is exhibiting at Clinical Operations in Oncology Trials West on April 24th and 25th in Burlingame, California.
The 2018 event is the 5th annual edition of the conference and brings together leading pharma and biotech professionals working in the oncology space from across the West Coast region.
“Fusion eClinical Suite provides uniquely tailored reports to support clinical oncology studies, including tumour response assessment and tracking, patient profiles, and biomarker reports. Axiom’s client roster includes many sponsors working on global oncology and plasma cell disorders including studies for the treatment of Multiple Myeloma, AML, CML, Hodgkin Lymphoma and Leukemia, among others. The easy-to-use, modular suite of tools is extremely flexible, enabling sponsors to manage all study data from Phase I to complex Phase III trials without having to change platforms or source additional vendors. It works exceptionally well for all studies, supporting US to global studies and enabling them to operate with far greater efficiency - speeding time to market,” shared Dr. Robert Arbeit, Chief Clinical Scientist.
Andrew Schachter, Founder and CEO concluded, “Our established ROI and delivery positions us as both cost efficient and best-in-class. We invite attendees to come and visit us at Booth 4 for a conversation and tailored demo over coffee.”
About Axiom Real-Time Metrics
Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: DM, Biostatistics and Pharmacovigilance. Axiom's eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.
Contact
[email protected]
+1.877.321.9191
PR Contact
Sarah Glofcheskie
[email protected]
+1.647.588.9073


OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 



